메뉴 건너뛰기
European Journal of Cancer
Volumn 82, Issue , 2017, Pages 16-24
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

(335)  Emile, Jean François kw,kx   Julié, Catherine kw,kx   Le Malicot, Karine ky   Lepage, Come ky,kz,la   Tabernero, Josep c,im   Mini, Enrico c,hi,lb   Folprecht, Gunnar c,er   Van Laethem, Jean Luc c,al   Dimet, Stéphanie lc   Boulagnon Rombi, Camille ld   Allard, Marc Antoine kw   Penault Llorca, Frédérique le   Bennouna, Jaafar ay   Laurent Puig, Pierre bc,la,lf   Taieb, Julien c,bc,lf   Thaler, Josef a   Greil, Richard b   Gaenzer, Johannes c   Eisterer, Wolfgang d   Tschmelitsch, Joerg e   more..

Author keywords

Biomarker; Colorectal carcinoma; Immune response; Prospective cohort study
Indexed keywords

B RAF KINASE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; RAS PROTEIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; TUMOR MARKER;
EID: 85021288157     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.04.025     Document Type: Article
Times cited : (39)
References (30)
  • 2
    • 6944230093 scopus 로고    scopus 로고
    • Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging
    • O'Connell, J.B., Maggard, M.A., Ko, C.Y., Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96 (2004), 1420–1425.
    • (2004) J Natl Cancer Inst , vol.96 , pp. 1420-1425
    • O'Connell, J.B.1    Maggard, M.A.2    Ko, C.Y.3
  • 3
    • 2542615200 scopus 로고    scopus 로고
    • Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    • André, T., Boni, C., Mounedji-Boudiaf, L., et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004), 2343–2351.
    • (2004) N Engl J Med , vol.350 , pp. 2343-2351
    • André, T.1    Boni, C.2    Mounedji-Boudiaf, L.3
  • 4
    • 80053619762 scopus 로고    scopus 로고
    • Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses
    • Yothers, G., O'Connell, M.J., Allegra, C.J., et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29 (2011), 3768–3774.
    • (2011) J Clin Oncol , vol.29 , pp. 3768-3774
    • Yothers, G.1    O'Connell, M.J.2    Allegra, C.J.3
  • 5
    • 84925231461 scopus 로고    scopus 로고
    • Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials
    • Schmoll, H.J., Twelves, C., Sun, W., et al. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. Lancet Oncol 15 (2014), 1481–1492.
    • (2014) Lancet Oncol , vol.15 , pp. 1481-1492
    • Schmoll, H.J.1    Twelves, C.2    Sun, W.3
  • 6
    • 84957568046 scopus 로고    scopus 로고
    • Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study
    • André, T., de Gramont, A., Vernerey, D., et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 33 (2015), 4176–4187.
    • (2015) J Clin Oncol , vol.33 , pp. 4176-4187
    • André, T.1    de Gramont, A.2    Vernerey, D.3
  • 7
    • 84870244259 scopus 로고    scopus 로고
    • Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
    • de Gramont, A., Van Cutsem, E., Schmoll, H.J., et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13 (2012), 1225–1233.
    • (2012) Lancet Oncol , vol.13 , pp. 1225-1233
    • de Gramont, A.1    Van Cutsem, E.2    Schmoll, H.J.3
  • 8
    • 84859403854 scopus 로고    scopus 로고
    • Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial
    • Alberts, S.R., Sargent, D.J., Nair, S., et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307 (2012), 1383–1393.
    • (2012) JAMA , vol.307 , pp. 1383-1393
    • Alberts, S.R.1    Sargent, D.J.2    Nair, S.3
  • 9
    • 84903547973 scopus 로고    scopus 로고
    • Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
    • Taieb, J., Tabernero, J., Mini, E., et al., PETACC-8 Study Investigators. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol 15 (2014), 862–873.
    • (2014) Lancet Oncol , vol.15 , pp. 862-873
    • Taieb, J.1    Tabernero, J.2    Mini, E.3
  • 10
    • 0022515473 scopus 로고
    • Lymphocytic infiltration and survival in rectal cancer
    • Jass, J.R., Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 39 (1986), 585–589.
    • (1986) J Clin Pathol , vol.39 , pp. 585-589
    • Jass, J.R.1
  • 11
    • 0023213901 scopus 로고
    • A new prognostic classification of rectal cancer
    • Jass, J.R., Love, S.B., Northover, J.M., A new prognostic classification of rectal cancer. Lancet 1:8545 (1987), 1303–1306.
    • (1987) Lancet , vol.1 , Issue.8545 , pp. 1303-1306
    • Jass, J.R.1    Love, S.B.2    Northover, J.M.3
  • 12
    • 29144514645 scopus 로고    scopus 로고
    • Effector memory T cells, early metastasis, and survival in colorectal cancer
    • Pagès, F., Berger, A., Camus, M., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353 (2005), 2654–2666.
    • (2005) N Engl J Med , vol.353 , pp. 2654-2666
    • Pagès, F.1    Berger, A.2    Camus, M.3
  • 13
    • 69149099591 scopus 로고    scopus 로고
    • CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study
    • Laghi, L., Bianchi, P., Miranda, E., et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 10 (2009), 877–884.
    • (2009) Lancet Oncol , vol.10 , pp. 877-884
    • Laghi, L.1    Bianchi, P.2    Miranda, E.3
  • 14
    • 58249089749 scopus 로고    scopus 로고
    • Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer
    • Salama, P., Phillips, M., Grieu, F., et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27 (2009), 186–192.
    • (2009) J Clin Oncol , vol.27 , pp. 186-192
    • Salama, P.1    Phillips, M.2    Grieu, F.3
  • 15
    • 84868632631 scopus 로고    scopus 로고
    • Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor
    • Allard, M.A., Bachet, J.B., Beauchet, A., et al. Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor. Diagn Pathol, 7, 2012, 156.
    • (2012) Diagn Pathol , vol.7 , pp. 156
    • Allard, M.A.1    Bachet, J.B.2    Beauchet, A.3
  • 16
    • 85010703183 scopus 로고    scopus 로고
    • Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 Trial
    • Taieb, J., Zaanan, A., Le Malicot, K., et al. Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 Trial. JAMA Oncol 14 (2016), 1–11.
    • (2016) JAMA Oncol , vol.14 , pp. 1-11
    • Taieb, J.1    Zaanan, A.2    Le Malicot, K.3
  • 17
    • 85019102288 scopus 로고    scopus 로고
    • Adjuvant FOLFOX +/− cetuximab in full RAS and BRAF wild type stage III colon cancer patients
    • Taieb, J., Balogoun, R., Le Malicot, K., et al. Adjuvant FOLFOX +/− cetuximab in full RAS and BRAF wild type stage III colon cancer patients. Ann Oncol 28 (2017), 824–830.
    • (2017) Ann Oncol , vol.28 , pp. 824-830
    • Taieb, J.1    Balogoun, R.2    Le Malicot, K.3
  • 18
    • 84926296479 scopus 로고    scopus 로고
    • Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
    • Blons, H., Emile, J.F., Le Malicot, K., et al. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol 25 (2014), 2378–2385.
    • (2014) Ann Oncol , vol.25 , pp. 2378-2385
    • Blons, H.1    Emile, J.F.2    Le Malicot, K.3
  • 19
    • 0033021439 scopus 로고    scopus 로고
    • High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability
    • Dolcetti, R., Viel, A., Doglioni, C., et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 154 (1999), 1805–1813.
    • (1999) Am J Pathol , vol.154 , pp. 1805-1813
    • Dolcetti, R.1    Viel, A.2    Doglioni, C.3
  • 20
    • 10244261646 scopus 로고    scopus 로고
    • Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers
    • Hayes, D.F., Bast, R.C., Desch, C.E., et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88 (1996), 1456–1466.
    • (1996) J Natl Cancer Inst , vol.88 , pp. 1456-1466
    • Hayes, D.F.1    Bast, R.C.2    Desch, C.E.3
  • 21
    • 70449420123 scopus 로고    scopus 로고
    • Use of archived specimens in evaluation of prognostic and predictive biomarkers
    • Simon, R.M., Paik, S., Hayes, D.F., Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101 (2009), 1446–1452.
    • (2009) J Natl Cancer Inst , vol.101 , pp. 1446-1452
    • Simon, R.M.1    Paik, S.2    Hayes, D.F.3
  • 22
    • 84980489465 scopus 로고    scopus 로고
    • Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: results of a worldwide consortium-based analysis of 1,336 patients
    • (abstr 3500) June
    • Galon, J., Mlecnik, B., Marliot, F., et al. Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: results of a worldwide consortium-based analysis of 1,336 patients. Presented at the annual ASCO meeting, Chicago, MI, June 2016 (abstr 3500).
    • (2016) Presented at the annual ASCO meeting, Chicago, MI
    • Galon, J.1    Mlecnik, B.2    Marliot, F.3
  • 23
    • 33749319703 scopus 로고    scopus 로고
    • Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
    • Galon, J., Costes, A., Sanchez-Cabo, F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
    • (2006) Science , vol.313 , pp. 1960-1964
    • Galon, J.1    Costes, A.2    Sanchez-Cabo, F.3
  • 24
    • 73349142719 scopus 로고    scopus 로고
    • In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer
    • Pagès, F.1, Kirilovsky, A., Mlecnik, B., et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27 (2009), 5944–5951.
    • (2009) J Clin Oncol , vol.27 , pp. 5944-5951
    • Pagès, F.1    Kirilovsky, A.2    Mlecnik, B.3
  • 25
    • 82555173112 scopus 로고    scopus 로고
    • Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy
    • Zaanan, A., Fléjou, J.F., Emile, J.F., et al. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res 17 (2011), 7470–7478.
    • (2011) Clin Cancer Res , vol.17 , pp. 7470-7478
    • Zaanan, A.1    Fléjou, J.F.2    Emile, J.F.3
  • 26
    • 84954026945 scopus 로고    scopus 로고
    • Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/− cetuximab: a pooled analysis of 3934 pts from the PETACC8 and N0147 trials
    • (abstr 3507)
    • Taieb, J., Le Malicot, K., Penault-Llorca, F., et al. Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/− cetuximab: a pooled analysis of 3934 pts from the PETACC8 and N0147 trials. J Clin Oncol, 33(15Suppl), 2015 (abstr 3507).
    • (2015) J Clin Oncol , vol.33 , Issue.15
    • Taieb, J.1    Le Malicot, K.2    Penault-Llorca, F.3
  • 27
    • 84922949171 scopus 로고    scopus 로고
    • Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes
    • Sinicrope, F.A., Shi, Q., Smyrk, T.C., et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 148 (2015), 88–99.
    • (2015) Gastroenterology , vol.148 , pp. 88-99
    • Sinicrope, F.A.1    Shi, Q.2    Smyrk, T.C.3
  • 28
    • 84962301577 scopus 로고    scopus 로고
    • Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
    • McGranahan, N., Furness, A.J., Rosenthal, R., et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351 (2016), 1463–1469.
    • (2016) Science , vol.351 , pp. 1463-1469
    • McGranahan, N.1    Furness, A.J.2    Rosenthal, R.3
  • 29
    • 84932628341 scopus 로고    scopus 로고
    • PD-1 blockade in tumors with mismatch-repair deficiency
    • Le, D.T., Uram, J.N., Wang, H., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
    • (2015) N Engl J Med , vol.372 , pp. 2509-2520
    • Le, D.T.1    Uram, J.N.2    Wang, H.3
  • 30
    • 84926207975 scopus 로고    scopus 로고
    • Histopathological features predict metastatic potential in locally advanced colon carcinomas
    • Jayasinghe, C., Simiantonaki, N., Kirkpatrick, C.J., Histopathological features predict metastatic potential in locally advanced colon carcinomas. BMC Cancer, 15, 2015, 14.
    • (2015) BMC Cancer , vol.15 , pp. 14
    • Jayasinghe, C.1    Simiantonaki, N.2    Kirkpatrick, C.J.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.